Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 476.4 DKK 2.23% Market Closed
Market Cap: 33.8B DKK

EV/EBITDA
Enterprise Value to EBITDA

-18.5
Current
-18
Median
4.4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-18.5
=
Enterprise Value
25.5B DKK
/
EBITDA
-1.4B DKK
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBITDA: 15.4
Negative Multiple: -18.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 942.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.1 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.5
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -650.3 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
45.1
2-Years Forward
EV/EBITDA
-587.7
3-Years Forward
EV/EBITDA
138.7